

References

L-217

1. OncoType DX Breast Cancer Assay: Healthcare Professionals website.
2. Baker J. Genomic Health, Inc. *Pharmacogenomics*. Apr 2007; 8(4):397-9.
3. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. *J Clin Oncol*. Nov 2007; 25(33):5287-5312.
4. Harris L, Ismaila N, McShane L, et al. American Society of Clinical Oncology 2016 Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. April 2016; 34(10):1134-50.
5. Paik S, Shak S, Tang G, et al. A multi-gene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med*. 2004; 351(27):2817-26.
6. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. *J Clin Oncol*. 2006; 24(23):3726-34.
7. Lo SS, Norton J, Mumby PB et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. *J Clin Oncol*. 2007; 25 (June 20 Supplement):577.
8. Oratz R, Paul D, Cohn AL, Sedlacek SM. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. *J Oncol Pract*. 2007; 3(4):182-8.
9. Asad J, Jacobson AF, Estabrook A, et al. Does Oncotype DX recurrence score affect the management of patients with early-stage breast cancer? *Am J Surg*. 2008; 196:527-9
10. Oncotype DX DCIS score predicts recurrence. *Cancer Discov*. Feb 2015;5(2):OF3.
11. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. V.2.2016.
12. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ; Panel members. Strategies for subtypes — dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Ann Oncol*. 2011 Aug; 22(8):1736-47.
13. Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. *Ann Oncol*, 2015; 26(8): 1533-1546.
14. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? *Genet Med*. 2009 Jan; 11(1):66-73.
15. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decision improve outcome in patients with breast cancer? *Genet Med*. 2016 Aug; 18(8):770-9.

16. Rakovitch E, Nofech-Mozes S, Hanna W, et al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. *Breast Cancer Research and Treatment*. Jul 2015;152(2):389-398.
17. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. *Journal of the National Cancer Institute*. May 15 2013;105(10):701-710.